StocksMedium•9 November 2026•
1 min read
ADC Therapeutics Reports $21M Q3 Revenue and Extends Cash Runway to 2029
Key Facts
1ADC Therapeutics reported Q3 2026 net product revenue of $21 million.
2The company holds $189.2 million in cash, extending its expected cash runway into 2029.
3The company announced that abstracts for ZYNLONTA were accepted for presentation at the ASH 2026 conference.
ADC Therapeutics reported Q3 2026 net product revenue of $21 million. The company stated in a PR Newswire release that it holds $189.2 million in cash and cash equivalents as of September 30, 2026, which extends its projected cash runway into 2029.
ADCT closed at $1.58 on November 6, 2026, as the company focuses on strengthening its balance sheet and advancing clinical opportunities for its primary product, ZYNLONTA. The company also announced that research abstracts for ZYNLONTA were accepted for presentation at the ASH 2026 conference following regulatory milestones in Japan.